Drug Profile
Research programme: bacteria based therapeutics - Seres Therapeutics
Alternative Names: Microbiome therapeutics - Seres Therapeutics; Microbiome therapies - Seres TherapeuticsLatest Information Update: 20 Jul 2022
Price :
$50
*
At a glance
- Originator Seres Health
- Developer Memorial Sloan-Kettering Cancer Center; Parker Institute for Cancer Immunotherapy; Seres Therapeutics; University of Texas M. D. Anderson Cancer Center
- Class Anti-inflammatories; Antineoplastics; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer; Inflammatory bowel diseases
- No development reported Metabolic disorders
Most Recent Events
- 20 Jul 2022 Preclinical development is ongoing USA (Seres Therapeutics pipeline July 2022)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 07 Feb 2019 Preclinical trials in Inflammatory bowel diseases in USA (unspecified route) before February 2019 (Seres Therapeutics Pipeline)